ArticleScience China. Life sciences2026
Broad synergistic effects of an AMP with multiple antibiotics against drug-resistant bacteria via multifaceted mechanisms.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) have emerged as promising alternatives or adjuncts to antibiotics. However, most studies on AMP-antibiotic combinations focus on specific drugs or pathogens, with limited exploration of broad-spectrum synergistic effects. Herein, we demonstrate that CATHPb1, a snake-derived AMP, exhibits extensive synergistic antimicrobial activity when combined with 12 antibiotics representing six distinct mechanisms of action. Moreover, CATHPb1 shows a low potential for inducing resistance and significantly enhances anti-biofilm and anti-persister activities in combination with antibiotics. The broad-spectrum synergy of CATHPb1 can be attributed to multiple mechanisms-including specific efflux pump inhibition, ROS generation, cell wall disruption, and DNA binding-distinct from the commonly observed membrane-disrupting activity. Notably, CATHPb1 markedly enhanced antibiotic efficacy in murine models of peritonitis and bacteremia, resulting in reduced bacterial loads of multidrug-resistant bacteria, decreased inflammatory responses, and improved survival rates. These findings underscore the therapeutic potential of CATHPb1 as a versatile adjuvant for combating multidrug-resistant bacterial infections.
Indexed as
Identifiers
41801541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.